<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>
</title>
</head>
<body>
<div class="page">
<p/>
<p>Powered by Editorial Manager&reg; and Preprint Manager&reg; from Aries Systems Corporation</p>
<p/>
</div>
<div class="page">
<p/>
<p>Powered by Editorial Manager&reg; and Preprint Manager&reg; from Aries Systems Corporation</p>
<p/>
</div>
<div class="page">
<p/>
<p>Patentometric Analysis of TB Vaccines using subject classification :  
a Case Study of the Technical Status of a Technological Domain  
</p>
<p> 
</p>
<p>PhD. Maidelyn D&iacute;az P&eacute;rez (first author) 
maidelyn@ict.upr.edu.cu 
Direction of Scientific Technical Information 
Group of Information and Knowledge Management (proGINTEC) 
University of Pinar del R&iacute;o (UPR), Cuba 
Phone (Work): 53 48 728642 
Phone (Mobile): 53 52 684746 
 
MSc. Raudel Gir&aacute;ldez Reyes 
Group of Information and Knowledge Management (proGINTEC) 
University of Pinar del R&iacute;o (UPR), Cuba 
 
MSc. Dayron Armas Pe&ntilde;a 
Group of Information and Knowledge Management (proGINTEC) 
University of Pinar del R&iacute;o (UPR), Cuba 
 
PhD. Egbert de Smet (corresponding author) 
egbert.desmet@ua.ac.be 
Institute of Education and Information Sciences 
University of Antwerp 
Gratiekapelstraat 10, 2000 Antwerpen, Belgium 
Phone : +32473980299  
Fax : +3232654328 
 
PhD. Mar&iacute;a Victoria Guzm&aacute;n 
Institute of Vaccine Research  
 
MSc. Romel Calero 
</p>
<p> 
 
MSc. Elio Aten&oacute;genes Villase&ntilde;or 
Industry Documentation Fund 
INFOTEC, Mexico 
 
PhD. Humberto Andr&eacute;s Carrillo Calvet 
Science Faculty and Center of Sciences of Complexity  
National Autonomic University of Mexico 
  </p>
<p/>
</div>
<div class="page">
<p/>
<p>Introduction 
</p>
<p>Patents are a technological indicator of significant relevance in studies of technological innovation 
</p>
<p>(Basberg 1982, 1983; Pavitt 1985; Grupp, Schmoch and Kuntze 1991; Narin 1995), and one of the most 
</p>
<p>reliable data sources for bio-informetric studies in the last decades (D&iacute;az-P&eacute;rez and Moya 2008). 
</p>
<p>Schmookler was the precursor of the use of patents as a technological indicator in a paper of 1966. A 
</p>
<p>patent is a measure of scientific-technological productivity. It is a document which communicates the 
</p>
<p>scientific advance like journal articles; indicating also that the resulting technology can be applied in 
</p>
<p>production processes, allowing a better performance in the transfers of technologies and licenses. The 
</p>
<p>bibliometric indicators comprise the patentometric studies (patent indicators) (Narinand Olivastro 1988; 
</p>
<p>Narin 1994; Bordons and Zulueta 1999; Spinak 1998; Gonz&aacute;lez-Albo and Zulueta-Garc&iacute;a 2007; Haupt et. 
</p>
<p>al. 2007; Corrocher et. al. 2007; Mart&iacute;nez-M&eacute;ndez et.al. 2010;Klitkou and Gulbrandsen 2010; Pao-Long, 
</p>
<p>Chao-Chan and Hoang-Jyh 2010). 
</p>
<p>Because of the potential use of the patent document, biotechnology has chosen patentometric studies as 
</p>
<p>one of its main research instruments to monitor the current status and future trends of science, to identify 
</p>
<p>emerging technologies and new fields of application of science in technology (Bhattacharya and Patra 
</p>
<p>2009).  Nanotechnology is one of the scientific domains that demonstrates the relevance of patent analysis 
</p>
<p>(Meyer and Persson1998; Hullmann and Meyer 2003; Meyer2000, 2001, 2006; Huang et. al. 2005; Sheu 
</p>
<p>et. al. 2006;Hullmann 2007; Bonaccorsi and Thoma 2007), mainly the area of nanotubes (Kuusi and 
</p>
<p>Meyer 2007; Gupta and Pangannaya 2000; Pao-Long, Chao-Chan and Hoang-Jyh 2010), showing the 
</p>
<p>relevance of patent metric studies in high impact areas (Li, Chen, Huang and Roco 2007; Leydesdorff and 
</p>
<p>Heimeriks 2001; Leydesdorff 2008a; Pei-Chun, Hsin-Ning, and Feng-Shang 2010). 
</p>
<p>Despite the importance of patent studies, most of patent analysis use frequency counts by years, countries, 
</p>
<p>assignees and inventors, while patentometric studies making analysis with a subject classification remain 
</p>
<p>scarce. 
</p>
<p>As stated by the norms established by the World Intellectual Property Organization (WIPO), every 
</p>
<p>invention must be attributed one or several classifications in the field number 51 of the patent document. 
</p>
<p>These classifications should identify and describe which areas of the technical knowledge the invention 
</p>
<p>belongs to. 
</p>
<p>The International Patent Classification (IPC) comprises the set of knowledge that can be considered to be 
</p>
<p>included in the scope of invention patents. As it is a unique and international system, it achieves a </p>
<p/>
</div>
<div class="page">
<p/>
<p>standardization in the taxonomies of the technological knowledge. It includes not only the bigger classes 
</p>
<p>and categories by disciplines, but also even the deepest complexity levels of each subject, reaching almost 
</p>
<p>to describe the proper results. 
</p>
<p>The hierarchical levels of the last version (eighth edition) of the IPC with its full structure of symbols 
</p>
<p>contains: 8 sections, 129 classes, 633 subclasses, 7066 groups and 10047 subgroups. This wide subject 
</p>
<p>coverage is what allows to perform metric analysis with this field of the patent document. 
</p>
<p>This research shares the criteria that the analysis by classification allows to perform a better mapping to 
</p>
<p>represent the underlying science in patent documents (Tijssen 1992; Leydesdorff 1987; Leydesdorff and 
</p>
<p>Vaugman 2005; Jaffe and Trajtenberg 2002; Leydesdorff 2004; Porter and Cunningham 2005). It also 
</p>
<p>allows to know the subject specialization by country, region and institutes (van Zeebroeck et. al. 2006; 
</p>
<p>Fall et. al. 2003; Cong and Han-Tong 2010). 
</p>
<p>The IPC can be used as the analysis unit to explore the information contained in patents (Dibiaggio and 
</p>
<p>Nesta 2005); and it can be even compared to the subject categories that the ISI attributes to journals, 
</p>
<p>according to Leydesdorff. This author trusts the classification classes as equivalents to those of the 
</p>
<p>journals, proposing to analyze the corresponding equivalent of a citation matrix between journal and 
</p>
<p>journal (Leydesdorff 2008b). Having these previous ideas in mind, this study proposes the use of the IPC 
</p>
<p>as another analysis unit beyond the application of the traditional patent indicators. 
</p>
<p>The research has as a main goal to perform an informetric analysis of a set of patents, weighing up the 
</p>
<p>international classification as another unit of analysis and measurement in the study, to obtain the 
</p>
<p>diagnosis of the composition of the technical status in technological domains. 
</p>
<p> 
Methodology and Procedures 
 
The methodology of this research, which was tested in previous researches with relevant results (D&iacute;az-
</p>
<p>P&eacute;rez and Moya-Aneg&oacute;n 2008; D&iacute;az-P&eacute;rez 2009; Gir&aacute;ldez, D&iacute;az-P&eacute;rez and Armas 2008; D&iacute;az-P&eacute;rez, 
</p>
<p>Rivero and Moya-Aneg&oacute;n 2010), is explained in the following paragraphs.  
</p>
<p>Database choice: 
</p>
<p>The data source selected is the United States Patents and Trademarks Office, using specifically the 
</p>
<p>granted patents database, because of the rich set of work possibilities and rigorous invention examination 
</p>
<p>process (Pavitt 1988; Michel and Bernd 2001; Trilateral Cooperation 2005; Borja Gonz&aacute;lez and Zulueta </p>
<p/>
</div>
<div class="page">
<p/>
<p>2007). In this database most of the candidate TB vaccines existing today under clinical trial can be found, 
</p>
<p>according to the official website Stop TB Partnership Working Group on New TB Vaccines. 
</p>
<p>Search strategy:  
</p>
<p>The search strategy was to interrogate the USPTO database on patent records granted between January 
</p>
<p>occur in the fields Title, Abstract and Claims. The truncation operator was used to cover all the 
</p>
<p>possibilities of apparition of these terms. 
</p>
<p>Strategy: (ttl/tuberculosi$ and ttl/vaccin$) or (abst/tuberculosi$ and abst/vaccin$) 
</p>
<p>or (aclm/tuberculosi$ and aclm/vaccin$). 
</p>
<p>184 patents granted by the USPTO about TB Vaccines were retrieved. 
</p>
<p>The date retrieved corresponds to the year the patent was granted, considering it more relevant as it means 
</p>
<p>newly constituted knowledge and innovations with trade opportunities. 
</p>
<p>The time span (and limitation) corresponds to the sample selected by the International Development 
</p>
<p>Project  Application of Analysis and Visualization Technologies of Biomedical Data of the Scientific 
</p>
<p>and Technological Cooperation Program between Cuba (CITMA) and Mexico (CONACYT). 
</p>
<p>Analysis unit: 
</p>
<p>Patents are considered units of technological capacity because they represent technological knowledge, 
</p>
<p>being used as units of study, computing and measurement of a domain. The bibliographic data obtained is 
</p>
<p>grouped by time, subject and geographical variables. 
</p>
<p>Data-processing: 
 
The tool used to download, normalize, process, analyze and visualize the data is the software proINTEC 
</p>
<p>(D&iacute;az-P&eacute;rez and Moya-Aneg&oacute;n 2008; D&iacute;az-P&eacute;rez, Rivero and Moya-Aneg&oacute;n 2010; Moya- Aneg&oacute;n, 
</p>
<p>Chinchilla, Corera and D&iacute;az-P&eacute;rez 2011). 
</p>
<p>Indicators of bibliometric origin were used but adapted in this case to the characteristics of patent 
</p>
<p>documents. The next lines show the equations of the complex indicators being used: 
</p>
<p> 
Indicator CPAPT=Amount of patents by year by country of the assignee 
 
</p>
<p> 
Indicator CPPT=Amount of patents by country of the assignee 
 
</p>
<p> 
Indicator CPPI=Amount of inventors by country of the inventor 
 </p>
<p/>
</div>
<div class="page">
<p/>
<p> 
Indicator CPAPI=Amount of patents by year by country of the inventor  
 
</p>
<p> 
Indicator CPIPI=Amount of patents by inventor by country of the inventor 
 
</p>
<p> 
Indicator CPTPT=Amount of patents by titular by country of the assignee 
 
</p>
<p> 
Indicator CPTC=Amount of patents by joint assignees 
 
</p>
<p> 
Indicator CPIC=Amount of patents by joint inventors 
 
</p>
<p> 
Indicator CPCIPs = Amount of patents by IPC [section] 
 
</p>
<p> 
Indicator CPPTSection=A=Amount of patents /section A by country of the assignee 
 
</p>
<p> 
</p>
<p>Indicator CPASection=A=Amount of patents / section A by year 
 
</p>
<p> 
Indicator CPPTSection=C=Amount of patents /section C by country of the assignee 
 
</p>
<p> 
Indicator CPASection=C=Amount of patents / section C by year 
 
</p>
<p> 
</p>
<p>Indicator CPPTSection=G=Amount of patents /section G by country of the assignee 
 
</p>
<p> 
Indicator CPASection=G=Amount of patents / section G by year 
 
</p>
<p> 
Indicator CPASection=G=Amount of patents / section G by year 
 
</p>
<p> 
Indicator CCT=Amount of citations by assignee 
</p>
<p> 
</p>
<p>Techniques: 
</p>
<p>Among the techniques for data visualization, the tabular form is used, through frequency counts in fields 
</p>
<p>of patents, diagrams, matrixes to visualize patent data through crossed variables; as well as networks 
</p>
<p>presented in the form of nodes or vertices, where the semantic structure is defined by the links connecting 
</p>
<p>these nodes. This last technique shows the patent analysis through technological maps, defining the visual 
</p>
<p>representations of the status of the domain, presenting graphically the results of the analysis in a 
</p>
<p>synthesized form. </p>
<p/>
</div>
<div class="page">
<p/>
<p>The visualization through networks makes it possible to represent the network links crossing variables to 
</p>
<p>find in this case, behaviors in the set of patents (joint assignees and inventors and linked subject areas). 
</p>
<p>Metric studies constitute a strong field of application for network techniques (Van Raan and Peters 1989; 
</p>
<p>Courtial and Callon 1991; Van Raan and Tijssen 1993; Verspagen 2007; Perianes-Rodr&iacute;guez, Olmeda-
</p>
<p>G&oacute;mez and Moya-Aneg&oacute;n 2010). In this case it is used the analysis of patent networks is used because it 
</p>
<p>allows to group patents by common characteristics in those critical fields of analysis, identifying 
</p>
<p>behaviors. Also, network analysis help the researcher to intuitively comprehend the whole data structure 
</p>
<p>of the domain under study (Yoon and Park 2004). 
</p>
<p>For a better representation of the information we used the Pathfinder pruning algorithm, widely used in 
</p>
<p>other studies (Moya-Aneg&oacute;n et. al. 2004; Guerrero-Bote et. al. 2006; Vargas-Quesada and Moya-Aneg&oacute;n 
</p>
<p>2007) because it allows to show only the more relevant links in the network. It is also used as a pruning 
</p>
<p>technique, the numerical limitation of the intensity of relationships in those nodes with few links. To 
</p>
<p>distribute the nodes in the visualization of the domain, the Springs Embedded spatial representation 
</p>
<p>algorithm is used, with the help of Netdraw to manipulate the graphs in the visual representations. 
</p>
<p>Results and Discussion 
</p>
<p>Case study: Tuberculosis Vaccines 
</p>
<p>Tuberculosis (TB) is one of the most prevalent and mortal infectious diseases (Aagaard, Dietrich, Doherty 
</p>
<p>and Andersen 2009). An estimate states that 1/3 of the world population is infected by Mycobacterium 
</p>
<p>tuberculosis (M. tuberculosis) and therefore subject to develop the disease. According to the World 
</p>
<p>Health Organization, every year around ten millions of cases and two millions of deaths are notified, 
</p>
<p>being the first cause of death in patients with the Acquired Immuno Deficiency Syndrome (AIDS). 
</p>
<p>There is only one vaccine available to prevent it, the Bacillus Calmette Gu&eacute;rin (BCG) (Calmette and 
</p>
<p>Gu&eacute;rin 1905,1909), but it induces an extremely variable protection (Mohd-Nor, Acosta and Sarmiento 
</p>
<p>2010). The effectiveness of the BCG vaccine has been assessed in several populations. For instance in a 
</p>
<p>study which took as the sample a native population in North America, it reported an index of 80% of 
</p>
<p>protection. However in another notable study performed in South India during the 60' and 70', its 
</p>
<p>protective effect was not present (Martin, Bigi and Gicquel, 2007). Although the BCG has shown an 
</p>
<p>impact against the most deadly forms of the disease during the childhood, it is debated its effectiveness in 
</p>
<p>the prevention of the Lung Tuberculosis in adults (form responsible for the biggest transmission of the 
</p>
<p>disease) and in the reactivation from infected individuals (Hesseling et. al. 2007). It has been also proved </p>
<p/>
</div>
<div class="page">
<p/>
<p>that the protective effect of the BCG has a decreasing behavior and therefore it is temporary (10-20 years) 
</p>
<p>(Aagaard, Dietrich, Doherty and Andersen 2009). 
</p>
<p>The World Health Organization (WHO) released in 1992 a report warning the world about the potential 
</p>
<p>risk of this epidemic disease, based on its reemergence in countries already infected, and its appearance in 
</p>
<p>developed countries where it was not present before. Accordingly the WHO announces a World 
</p>
<p>Emergency about Tuberculosis. 
</p>
<p>Productivity by years and countries 
 
The time series obtained evidence a notorious quantitative change in the rate of production of patents in 
</p>
<p>the decade of the nineties. During 21 years, between 1976 and 1997, only 9 patents were granted. 
</p>
<p>However, in the year 1998, 10 patents were granted and from there on, until 2011, the production rate 
</p>
<p>remained in between 4 and 18 patents per year, with a mean of 11 patents per year (Fig. 1). 
</p>
<p>The production of 2011 contrasts with the behavior during the period of 1998-2010, being granted 33 
</p>
<p>patents in this year. That means an increase of the 300% related to the mean production value of the 
</p>
<p>preceding 13 years.  
</p>
<p> 
</p>
<p>Fig. 1: Patents by year in TB Vaccines 
Source: Software proINTEC 
</p>
<p> 
This notorious increase in the productivity rate has the precedent of the apparition of the AIDS disease, 
</p>
<p>because it causes the death of a high number of people infected by tuberculosis. This situation allowed the 
</p>
<p>reemergence of TB even in very developed countries where the disease was not present before. It was a 
</p>
<p>key factor for bigger economical investments to support the scientific research, and propitiated the World 
</p>
<p>Health Organization (WHO) declaration of the world-wide emergency on tuberculosis in 1992.  
</p>
<p>Also this increase in the late nineties, sustained during the first decade of the new century, is correlated in 
</p>
<p>time with significant biotechnological advances and scientific findings: new technologies for sequencing 
</p>
<p>biological macromolecules, the development of microarray analysis techniques, the publication of the </p>
<p/>
</div>
<div class="page">
<p/>
<p>Genome Sequence of Tuberculosis in the prestigious journal Nature (Cole, et. al., 1998); new DNA 
</p>
<p>(Lozes et. al., 1997; Denis et. al., 1998; Baldwin et. al., 1999; Li Z et. al, 1999).  
</p>
<p>The patentometric analysis by country shows the following scheme of development of TB Vaccines: 
</p>
<p>United States (95 patents) in the first place, which corresponds to the great number of research centers 
</p>
<p>focused on its study, followed by France (15 patents) and United Kingdom (12 patents), being both, 
</p>
<p>countries with a great technological development in this subject area; followed by Denmark, Germany, 
</p>
<p>and Belgium (Table I). Despite the severe danger which Tuberculosis means to humanity, only 21 
</p>
<p>countries figure as holders of registered inventions in the USPTO. 
</p>
<p>India and Japan have only 2 granted patents in the USPTO respectively, despite having a relatively high 
</p>
<p>prevalence of cases of the disease (Mori, 2000; WHO, 2009). For instance, India has the fifth part of its 
</p>
<p>population infected by Tuberculosis, according to the WHO Official Says. Every year two million people 
</p>
<p>develop the active TB more than in any other country in the world. 
</p>
<p>This study proves that the technological productivity in terms of patents by countries does not correspond 
</p>
<p>to the severity in which this disease affects them (number of deaths and infections by TB). The same 
</p>
<p>happens with the scientific productivity, the countries with the higher productivity of articles are not the 
</p>
<p>countries with a high incidence of cases of TB, according to a recent study on the subject (Guzm&aacute;n, 
</p>
<p>Carrillo and Jim&eacute;nez 2010). 
</p>
<p>On the other hand, the behavior of the patent-holdership indeed corresponds to the productivity by 
</p>
<p>country (Fig. 2). The US has 43 assignees in the USPTO with an average of one patent by assignee. With 
</p>
<p>a similar average, it is followed in number of assignees by the UK with 7. France, that has the second 
</p>
<p>position in the ranking of total production by country have registered 15 patents with 4 assignees. 
</p>
<p>Outstandingly, with a single holder, Denmark and Belgium have 9 and 7 registered patents respectively, 
</p>
<p>while Germany and Canada with a lower number of patents have a bigger number of assignees 
</p>
<p>developing its researches. 
</p>
<p>Because of its relevance, the group of researchers by country working in this subject was analyzed 
</p>
<p>(Fig.3). 
</p>
<p>In United States, 132 researchers have worked in inventions related to TB Vaccines, in France 33 and in 
</p>
<p>the United Kingdom 31. This movement of researchers corresponds to the technological development in 
</p>
<p>these leading countries, owning the source of the protected knowledge and the main scientific potential 
</p>
<p>integrating the research front in TB Vaccines. </p>
<p/>
</div>
<div class="page">
<p/>
<p>  </p>
<p/>
</div>
<div class="page">
<p/>
<p>Table 1: Patents by year and country of assignee 
 Source: proINTEC 
</p>
<p>Conntries(Assig)/Years 1988 1992 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 Total 
UnitedStates of America  2 1 1 1 6 3 5 11 8 8 9 1 4 3 5 4 8 15 95 
France      1 2 1  4  1 1 1 1    3 15 
United Kingdom (Great 
Britain) 1        2 2 1   1   1 2 2 12 
</p>
<p>Denmark       1 1   1   2    1 3 9 
Belgium      1 2    2   1 1     7 
Germany           1 3      2 1 7 
Canada         3  1      1   5 
Korea, Republic of      1         1    2 4 
Australia                1   2 3 
Sweden             2      1 3 
India            1     1   2 
Israel                   2 2 
Italy         1         1  2 
Japan                  2  2 
Switzerland              1     1 2 
China                 1   1 
Finland                 1   1 
Iceland       1             1 
Netherlands                   1 1 
New Caledonia         1           1 
Spain                1    1 
Total 1 2 1 1 1 9 9 7 18 14 14 14 4 10 6 7 9 16 33 176 
</p>
<p> 
 
</p>
<p> 
</p>
<p>Fig. 2: Amount of assignees by country of the assignee 
Source: proINTEC 
</p>
<p> 
</p>
<p>They are followed in number of researchers by country by: Germany (17), Denmark (17), Canada (11) 
</p>
<p>and Korea (16 researchers). 
</p>
<p>An interesting point in this analysis is the representation of China with 19 researchers, occupying one of 
</p>
<p>the first positions in the graph of countries of inventors (Fig. 3). This shows their scientific potential in 
</p>
<p>terms of human resources focused on researching TB Vaccines, even when it does not appear as an 
</p>
<p>assignee in the patents of USPTO. 
</p>
<p> </p>
<p/>
</div>
<div class="page">
<p/>
<p>It is important to highlight how researchers from Russia, Estonia, Austria and Mexico are also among the 
</p>
<p>current research front in TB Vaccines even when their countries are not included as assignees in the 
</p>
<p>USPTO (Fig. 3). 
</p>
<p> 
</p>
<p>Fig. 3: Amount of Inventors by country of the Inventor 
Source: proINTEC 
</p>
<p> 
Productivity by Inventors and Assignees 
</p>
<p>The kernel of researchers in the creation of technology related to TB Vaccines within the USPTO consists 
</p>
<p>of 359 inventors. There are 184 granted patents, giving us a yearly average of almost 2 patents per 
</p>
<p>inventor during the period 1976-2011. There is a group of 21 inventors that have participated in the 
</p>
<p>creation of more than 5 patents granted by USPTO (Fig. 4). 
</p>
<p> 
</p>
<p>Fig. 4: Main Inventors (more than 5 patents) 
Source: proINTEC 
</p>
<p> 
</p>
<p>Analyzing the inventive activity of the discipline by year to identify the inventors who work on the TB 
</p>
<p>Vaccines subject more consistently, we found that there are 41 researchers to whom more than 1 patent </p>
<p/>
</div>
<div class="page">
<p/>
<p>was granted in one year. Table II identifies the main researchers currently working more systematically in 
</p>
<p>prophylactic alternatives against TB. The table also shows that the inventive activity by inventor has 
</p>
<p>increased after year 1999 where inventors with 2 patents about TB Vaccines in a year can be seen. 
</p>
<p>Table 2: Patents by Inventors by Year (more than 1 patent in a year) 
Source: proINTEC 
</p>
<p> 
Inventors/Years 1999 2001 2002 2003 2004 2005 2006 2009 2010 2011 Total 
</p>
<p>Campos-Neto; Antonio       2           6 8 
Skeiky; Yasir A. W.       2           6 8 
Dillon; Davin C.       2           3 5 
Gennaro; Maria Laura               2   3 5 
Sadoff; Jerald C.                 2 3 5 
Andersen; Peter             2     2 4 
Content; Jean 2     2             4 
De Bruyn; Jacqueline 2     2             4 
De Wit; Lucas 2     2             4 
Jacobs, Jr.; William R. 2               2   4 
Pescher; Pascale 2   2               4 
Lodes; Michael J.                   4 4 
Marchal; Gilles 2   2               4 
Romain; Felix 2   2               4 
Hone; David Michael                   3 3 
Horwitz; Marcus A.         3           3 
Houghton; Raymond L.                   3 3 
Jen; Shyian                   3 3 
Ovendale; Pamela                   3 3 
Riley; Lee W.   3                 3 
Twardzik; Daniel R.                   3 3 
Vedvick; Thomas S.                   3 3 
Bloom; Barry R.       2             2 
Brosch; Roland                   2 2 
Cole; Stewart                   2 2 
Hess; Jurgen         2           2 
James; Brian W.                   2 2 
Johnston; Stephen A.         2           2 
Kaufmann; Stefan H. E.         2           2 
Laal; Suman                 2   2 
Laqueyrerie; Anne     2               2 
Marsh; Philip                   2 2 
McGuire; Michael J.         2           2 
Reed; Steven G.                   2 2 
Sambandamurthy; Vasan                 2   2 
Schroder; Ulf           2         2 
Skjot; RikkeLouiseVinther                   2 2 
Sun; Ronggai                 2   2 
Svenson; Stefan           2         2 
Xu; Bai                   2 2 
Zolla-Pazner; Susan                 2   2 
Total 14 3 8 14 11 4 2 2 12 59 129 
</p>
<p> 
 
</p>
<p>In the analysis of the science-technology relationship, it became clear that the inventors of this 
</p>
<p>technological domain have an active scientific life. This pattern matches several criteria stating that 
</p>
<p>inventor scientists tend to publish much more than non-inventor scientists, even years after obtaining the 
</p>
<p>patent still a scientific activity around the patent can be observed (Van Looy et. al. 2006). </p>
<p/>
</div>
<div class="page">
<p/>
<p>This is due to the fact that applied research activities are related to basic research activities (Carayol 
</p>
<p>2003), or in other words, patents stimulate the production of articles. It is even said that in the 
</p>
<p>biotechnology sector more than 50% of the citations in patents refer to scientific publications (Jaques 
</p>
<p>2001).This behavior can be observed  in the main inventors of this domain, who have a prolific scientific 
</p>
<p>productivity, for instance: 
</p>
<p>- Skeiky (Skeiky and  Sadoff  2006; Skeiky et. al. 2004a,b; Skeiky and Sadoff 2006; Skeiky et. al. 
</p>
<p>2009) 
</p>
<p>- Horwitz (Horwitz, Harth, Dillon and Maslesa-Galic 2000; Horwitz et. al. 1995; Horwitz et. al. 
</p>
<p>2005) 
</p>
<p>- Kaufmann (Kaufmann 2002; Kaufmann and  McMichael2005; Kaufmann, Hussey and Lambert 
</p>
<p>2010; Kaufmann 2010; Kaufmann 2011); 
</p>
<p>- Cole (Cole et. al.1998; Cole 1999; Cole 2000);  
</p>
<p>- Andersen (Andersen1994a, b; Andersen, Andersen, Sorensen and Nagai 1995; Andersen1997; 
</p>
<p>Aagaard, Dietrich, Doherty and Andersen 2009) 
</p>
<p> 
The main analyzed  inventors are from United States, France, Belgium, Denmark, Germany and Canada 
</p>
<p>(Map 1), in rather close correspondence with the more productive countries. 
</p>
<p> 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inventores 
</p>
<p> 23 Relacion(es)  1 Relacion(es) (Pa&iacute;ses) 
 14 Patentes  4 Patentes 
</p>
<p>Map1:Patents of Inventors by countries (more than 3 patents of the inventor by country) 
Source: proINTEC 
</p>
<p> 
</p>
<p>The assignees spectrum in this domain has a heterogeneous composition. The biggest percent of assignees 
</p>
<p>is formed by companies, followed by universities which include hospitals serving as teaching units; then </p>
<p/>
</div>
<div class="page">
<p/>
<p>the research institutes and foundations and societies supporting the research. And with a minimal share, 
</p>
<p>natural persons and government entities (Graph1). 
</p>
<p> 
</p>
<p>Graph 1: Assignees spectrum 
</p>
<p>This analysis shows that TB Vaccines is a sector of science developed exclusively by researchers and 
</p>
<p>academics who need infrastructure and resources to develop their work, that is why their potential is 
</p>
<p>located in companies with resources, universities who hold knowledge and institutes where both 
</p>
<p>requisites are fulfilled. 
</p>
<p>The main assignees of the inventions recorded about TB Vaccines are the Institut Pasteur from France 
</p>
<p>located in Paris, and the Corixa Corporation from United States located in Seattle, with 13 and 14 patents 
</p>
<p>respectively. 
</p>
<p> 
</p>
<p>Fig.5: Amount of patents by assignee (with more than 1 patent) 
Source: proINTEC 
</p>
<p> 
</p>
<p>There are also other assignees with technological productivity about TB Vaccines: The Regents of the 
</p>
<p>University of California (United States), Statens Serum Institut (Denmark), Cornell Research Foundation, </p>
<p/>
</div>
<div class="page">
<p/>
<p>Inc. (United States), N.V. Innogenetics S.A. (Belgium), Albert Einstein College of Medicine of Yeshiva 
</p>
<p>University (United States), Aeras Global TB Vaccine Foundation (United States), The Board of Trustees 
</p>
<p>of the Leland Stanford Junior University (United States) and University of Medicine and Dentistry of New 
</p>
<p>Jersey (United States)(Fig. 5). 
</p>
<p>In Map 2 the fact is highlighted that most of the most productive assignees belong to the United States. 
</p>
<p>Besides representing the most productive assignees from the leading countries in the subject, the map 
</p>
<p>shows the most productive assignee of Denmark, Belgium, Germany, Canada, Switzerland and Korea 
</p>
<p>(Map 2). These countries are emerging nowadays with patentable researches about Vaccines in the last 
</p>
<p>years. 
</p>
<p> 
 
</p>
<p> 
</p>
<p>Titulares 
 19 Relacion(es)  1 Relacion(es) (Pa&iacute;ses). 
</p>
<p> 14 Ocurrencia(s)  2 Ocurrencia(s) 
 
</p>
<p>Map 2:Patents by assignees by countries (more than 1 patent by assignee by country) 
Source: proINTEC 
</p>
<p> 
Joint relationships among assignees and inventors in the domain of TB Vaccines 
 
A group of assignees have worked jointly in this domain to generate technologies related to TB Vaccines 
</p>
<p>(Map 3). The most noticeable relationships among them are for instance: Virginia Polytechnic Institute 
</p>
<p>and State University, Board of Supervisors of Louisiana State University and Agricultural and 
</p>
<p>Mechanical College, and Board of Regents for Oklahoma State University, they are all assignees from  
</p>
<p>the United States. 
</p>
<p>The main research relationships are established in a bigger percent with academic research centers.  </p>
<p/>
</div>
<div class="page">
<p/>
<p>CorixaCorporation is the biggest producer but it does not have joint collaboration relationships with any 
</p>
<p>other research center(Map 3). 
</p>
<p>The Institut Pasteur from France has done joint research with another institute. 
</p>
<p> 
</p>
<p> 3 Relations  1 Relations (Holders) 
 1 Occurrence(s)  1 Occurrence(s)  
</p>
<p> 
Map 3: Joint Assignees in the domain TB Vaccines 
</p>
<p>Source: proINTEC 
 
</p>
<p>The relationships between research centers, institutes and academies, generate relationships between their 
</p>
<p>researchers. There is a wide group of inventors in this domain who have worked jointly in the 
</p>
<p>development of patents. The collaborators in the TB Vaccines domain, who mostly correspond to the 
</p>
<p>most technologically productive of the domain, are presented in Map 4. 
</p>
<p> </p>
<p/>
</div>
<div class="page">
<p/>
<p> </p>
<p> 10 Relations  1 Relations (Inventors) 
 12 Occurrence(s)  4 Occurrence(s) 
</p>
<p> 
 Map 4: Joint inventors of the domain TB Vaccines (more than 3 patents) 
</p>
<p>Source: proINTEC 
 
The most intense collaboration link is established between the two more productive inventors of the 
</p>
<p>domain, Antonio Campos Neto and Yasir A.W. Skeiky. It is followed in intensity by the relationship with 
</p>
<p>other researchers like David Dillon. This could indicate that they belong to the same research team, 
</p>
<p>because they all belong to United States and the Corixa Corporation. 
</p>
<p> 
Subject productivity: international patent classification (IPC) 
 
This domain is comprised by 4 areas of the IPC. The biggest number of technological innovations belong 
</p>
<p>to the area COMMON LIFE NEEDS (A), followed by CHEMISTRY AND METALURGICS (C), 
</p>
<p>PHYSICS (G) and DIVERSE INDUSTRY TECHNIQUES  TRANSPORTS (B) (Fig. 6).  
</p>
<p> 
</p>
<p>Fig. 6: Patents by IPC sections 
Source: proINTEC 
</p>
<p>Section A 
</p>
<p>When each classification is analyzed separately, there are 20 countries working in section A, which 
</p>
<p>correspond relatively to the productivity by countries (Fig. 7). While France is the second country with 
</p>
<p>highest number of patents of the domain, it is in the fifth position in this section (Fig. 7). This could mean </p>
<p/>
</div>
<div class="page">
<p/>
<p>that their researches in this subject are mostly oriented towards other uses and applications and diagnostic 
</p>
<p>techniques.  
</p>
<p> 
</p>
<p> 
</p>
<p>          Fig. 7: Patents by country of the assignee of section A (IPC)     Fig. 8: Patents section A by year 
Source: proINTEC 
 
</p>
<p>- rich representation and increase of section A, appearing since 2001 with 16 patents, reaching 27 
</p>
<p>patents in 2011 (Fig.8) 
</p>
<p>- the predominance of section A might be because it groups patents related mostly with liposomes 
</p>
<p>and other forms of long lasting release, key technologies for the elaboration of vaccine 
</p>
<p>compounds 
</p>
<p>Section C 
</p>
<p>15 countries have patented technological results related to CHEMISTRY, with patents classified under 
</p>
<p>section C, less than in section A(Fig. 9). France goes to the second place in researches related to section 
</p>
<p>C, and Korea goes to the sixth place.  
</p>
<p> 
</p>
<p>Fig. 9: Patents by country of the assignee of section C (IPC)                        Fig. 10: Patent section C(IPC) by years 
Source: proINTEC 
 </p>
<p/>
</div>
<div class="page">
<p/>
<p>- the analysis by year shows systematic work in this subject, with 2011 as the year with the 
</p>
<p>highest number of results related to Chemistry (Fig. 10) 
</p>
<p>- this behavior might be because Section C groups patents related to nucleic acids, genetic 
</p>
<p>engineering techniques including genetic manipulation, creation of  recombinant strands, work 
</p>
<p>with plasmid vectors and bacteriophages, peptides, viruses and vectors, technologies that have 
</p>
<p>been developed in the world to perform prophylactic control. 
</p>
<p>Section G 
</p>
<p>Only 8 countries are researching in the PHYSICS (G) section (Fig. 11). In this area the United Kingdom 
</p>
<p>moves to the sixth place in amount of patents, with countries like Canada, Australia and India among the 
</p>
<p>first positions. A remarkable fact is that one of the two patents granted to India in the USPTO, is related 
</p>
<p>to Physics, holding the G classification. 
</p>
<p>- in general only emerging countries are working in this classification inside this domain 
</p>
<p>- it is shown that patents on TB Vaccines related to Physics start appearing in 1998, linking to this 
</p>
<p>classification since then in almost all the years investigated 
</p>
<p>- section G groups patents mainly about immunology methods or trials and trials for 
</p>
<p>microorganism studies; and about support for the immobilization of immunology compounds, 
</p>
<p>which are all technological strategies widely used today in the creation of vaccines 
</p>
<p> 
</p>
<p> 
Fig. 11: Patents by country of the assignee in section G (IPC)          Fig. 12: Patents by year in section G (IPC) 
</p>
<p>Source: proINTEC 
 
</p>
<p>Section B 
</p>
<p>And lastly, only one patent is related to section DIVERSE INDUSTRY TECHNIQUES  TRANSPORTS 
</p>
<p>(B). It was granted to France in the year 2002, being the only country having researched in this subject 
</p>
<p>area inside the TB Vaccines domain. </p>
<p/>
</div>
<div class="page">
<p/>
<p>Section B groups patents related mainly to packaging, presentation forms, filling and emptying. An 
</p>
<p>example of this is the patent with this classification in this study. It is related to a device, a dispenser and 
</p>
<p>spreading method for mucosal vaccines. 
</p>
<p>Joint classifications 
</p>
<p>The joint classifications established in this domain reveal the relationships between the different areas of 
</p>
<p>techniques to generate new patentable technologies. In this case there are noticeable relationships 
</p>
<p>between sections A and C, and also some links with specific areas inside this sections with a subject area 
</p>
<p>of section G (Map 5).  
</p>
<p> 
</p>
<p> 10 Relations  1 Relations (CIP) 
 25 Occurrence(s)  1 Occurrence(s)  
</p>
<p>Map 5: Joint subclasses (IPC) of the domain TB Vaccines 
Source: proINTEC 
</p>
<p> 
This analysis proves that in this domain there are some technological associations between classifications 
</p>
<p>of sections A and C to obtain possible candidate vaccines; there are also patents using specific knowledge 
</p>
<p>from one field of Physics (G1N) to generate inventions about TB Vaccines. 
</p>
<p>Citations to Patents 
</p>
<p>Patents from Corixa Corporation from United States are the most cited ones, as proven  by the analysis of 
</p>
<p>citations by assignee. The next in amount of citations are the patents from Statens Serum Institut from 
</p>
<p>Denmark, then the inventions from The Regents of the University of California (United States), and the 
</p>
<p>findings of the Albert Einstein College of Medicine of  YeshivaUniversity (United States) among the 
</p>
<p>most cited assignees(Fig.13). 
</p>
<p>However, the most outstanding result was to find among the most cited ones, some assignees who are not 
</p>
<p>among the first places according to their productivity. In this case there are for instance: Galenica 
</p>
<p>Pharmaceuticals, Inc. (United States), The Johns Hopkins University (United States) and The Public 
</p>
<p>Health Research Institute of the City of New York, Inc. (United States)(Fig.13). </p>
<p/>
</div>
<div class="page">
<p/>
<p>This behavior indicates that the claims of patents from these assignees have constituted significant 
</p>
<p>outcome to generate other technologies, and even when they are not among the most productive assignees 
</p>
<p>in the USPTO, their patents have become technological precedents of high relevance in the TB Vaccines 
</p>
<p>domain. 
</p>
<p> 
</p>
<p> 
</p>
<p> 
Fig.13: Amount of citations by assignee of the patent (more than 1 cite).   
</p>
<p>Source: proINTEC 
</p>
<p>A numerous representation of universities can be seen among the assignees in the citation analysis. This 
</p>
<p>evidences the relevance of the Academy in the development of scientific researches, and an adequate flow 
</p>
<p>of scientific-technological information between the main assignees in the research front of TB Vaccines. 
</p>
<p>The citation indicator is one of the relatively more reliable measures to assess the value of patents (D&iacute;az-
</p>
<p>P&eacute;rez and Moya-Aneg&oacute;n 2008). In this case it is shown that the main assignees working in the subject in 
</p>
<p>the world, are those who receive more citations; their patents are assessed through citation as an important 
</p>
<p>research start inside the TB Vaccines domain. 
</p>
<p> 
Conclusions 
 
The work methodology being used, which included the possibility to use the international patent 
</p>
<p>classification as another analysis and measurement unit for technological domains, allowed to diagnose 
</p>
<p>the composition of the technical status of the case study. Some significant aspects of the technical status 
</p>
<p>of the Tuberculosis Vaccines domain in the next listing evidence it: 
</p>
<p>- the productivity maximums in patents about TB Vaccines correspond to the main scientific facts 
</p>
<p>published about the subject 
</p>
<p>- the geographical projection of the domain is centered and more technologically covered in highly 
</p>
<p>developed countries, not in countries with the highest numbers of infections and deaths because 
</p>
<p>of TB </p>
<p/>
</div>
<div class="page">
<p/>
<p>- the countries with emerging patentable researches about TB Vaccines are Denmark, Belgium, 
</p>
<p>Germany, Canada, Switzerland and Korea 
</p>
<p>- the most productive researchers in prophylactic alternatives against TB come mainly from United 
</p>
<p>States, France, Belgium, Denmark, Germany and Canada 
</p>
<p>- a strong link between the basic science and the technological innovation exists in this domain, 
</p>
<p>originated in the flow of scientific-technological knowledge of its inventors 
</p>
<p>- the assignees spectrum is composed mostly by companies (51.49%); followed by universities 
</p>
<p>(26,97%) including hospitals and docent units; research institutes (14.61%) including also 
</p>
<p>foundations and societies supporting research institutes; with a minimal share for natural persons 
</p>
<p>(3.37%) and government entities (2.25%) 
</p>
<p>- most of the collaboration is established with assignees from United States. The main research 
</p>
<p>relationships are established with research and academic centers 
</p>
<p>- the most cited assignees are the universities, showing an apparent flow of scientific-technological 
</p>
<p>information between the main assignees. These patents become an important research entry in the 
</p>
<p>domain through citation. 
</p>
<p>The classification analysis allowed to identify the technological specialization of the domain, splitting its 
</p>
<p>composition by subject areas. Each subject corresponded to topics of the different technological strategies 
</p>
<p>being used in the world to develop candidate vaccines against TB. 
</p>
<p>The IPC analysis shows that classification studies ease the representation of the underlying science in 
</p>
<p>patent documents. It also allows to define the subject specialization by countries and years, the IPC being 
</p>
<p>an essential and strategic indicator in the subject analysis of technological domains.  
</p>
<p>Acknowledgements 
International Development Project  Application of Analysis and Visualization Technologies of 
</p>
<p>Biomedical Data inside the Scientific and Technological Cooperation Program between Cuba (CITMA) 
</p>
<p>and Mexico (CONACYT).Specially to the Laboratory of non-Lineal Dynamics of the Sciences Faculty of 
</p>
<p>the  
</p>
<p> 
</p>
<p>  </p>
<p/>
</div>
<div class="page">
<p/>
<p>References 
 
Aagaard, C., Dietrich, J., Doherty, M. and Andersen, P. (2009).TB vaccines: current status and future 
perspectives.Immunology and  Cell Biology, 87, 279 286. 
 
Andersen P. (1997). Host responses and antigens involved in protective immunity to Mycobacterium 
tuberculosis. J Immunol, 45,115-131. 
 
Andersen, P., Andersen, A.B, Sorensen, A.L. and Nagai, S.(1995). Recall of long-lived immunity to 
Mycobacterium tuberculosis infection in mice. J. Immunol., 154, 3359-3372. 
 
Andersen P. (1994a). The T cell response to secreted antigens of Mycobacterium tuberculosis. 
Immunobiology, 191, 537 47. 
 
Andersen P. (1994b). Effective vaccination of mice against Mycobacterium tuberculosis infection with a 
soluble mixture of secreted mycobacterial proteins. Infect Immun,62, 2536 44. 
 
Baldwin S.L. et.al.(1999).Immunogenicity and protective efficacy of DNA vaccines encoding secreted 
and non-secreted forms of Mycobacterium tuberculosis Ag85A.TuberLungDis, 79, 251 9. 
 
Basberg, B.  (1982).Technological change  in  the Norwegian whaling industry: A  case-study  in  the  use  
of  patent-statistics  as  a  technology indicator. Research Policy, 11,163-171. 
 
Basberg, B.  (1983). Foreign patenting in the U.S. as a technology indicator: The case  of  Norway. 
Research Policy, 12, 227-237. 
 
Bhattacharya, S. and Patra, S.K. (2009).Patent as an Indicator of Technological Capability: Case Study 
based on Indian Patenting Activity in the Biotechnology Sector. Proceedings of ISSI, 1, 516-527.      
 
Bonaccorsi, A. and Thoma, G. (2007). Institutional complementarity and inventive performance in 
nanoscience and technology. Research Policy, 36, 813 831. 
 
Bordons, M. and Zulueta, M. (1999). Evaluaci&oacute;n de la actividad cient&iacute;fica a trav&eacute;s de indicadores 
bibliom&eacute;tricos. Revista Espa&ntilde;ola de Cardiolog&iacute;a, 52 (10), 790-800. 
 
Borja Gonz&aacute;lez, A. and Zulueta, M.A. (2007). Estudio comparativo de bases de datos de patentes en 
internet. Anales de Documentaci&oacute;n, 10, 145-162. 
 
Calmette, A. and Gu&eacute;rin, C. (1905).Origine intestinale de la tuberculosepulmonaire.Ann Inst Pasteur, 19, 
601 18. 
 
Calmette, A. and Gu&eacute;rin, C. (1909). Sur quelque spropri&eacute;t&eacute;s du bacillituberculeux  bovine, 
cultiv&eacute; sur la bile de boeuf glyc&eacute;rin&eacute;e. Compt Rend. AcadSci, 149, 716 18. 
 
Carayol, N. (2003). Objectives, agreements and matching in science-industry collaborations: 
reassembling the pieces of the puzzle. Research Policy,32 (6), 887-908. 
 
Cole, S.T.et. al. (1998).Deciphering the biology of Mycobacterium Tuberculosis from the complete 
genome sequence.Nature, 11, 393(6685), 537-44. 
 
Cole, S.T. (1999). Learning from the genome sequence of Mycobacterium tuberculosis H37Rv. FEBS 
Lett, 452, 7 10. 
 
Cole, S.T. (2002). Comparative mycobacterial genomics as a tool for drug target and antigen 
</p>
<p>discovery.Eur Respir J Suppl, 36, S78 S86. 
 
Cong, H. and Han-Tong, L.(2010). Pattern-oriented associative rule-based patent classification. Expert 
Systems with Applications, 37, 2395 2404. 
 </p>
<p/>
</div>
<div class="page">
<p/>
<p>Corrocher, N., Malerba, F., and Montobbio, F. (2007).Schumpeterian patterns of innovative activity in 
theICT field. Research Policy, 36, 418 432. 
 
Denis, O.et. al. (1998). Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a 
CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium Tuberculosis 
H37Rv infection. InfectImmun, 66(4), 1527 33. 
 
D&iacute;az-P&eacute;rez, M. (2009).Situaci&oacute;n de las metodolog&iacute;as para la medici&oacute;n de la ciencia, la tecnolog&iacute;a y la 
innovaci&oacute;n en Am&eacute;rica Latina.ACIMED, 19 (4). 
 
D&iacute;az-P&eacute;rez, M. and Moya- Aneg&oacute;n, F.(2008). El An&aacute;lisis de Patentes como Estrategia Oportuna para la 
Toma de Decisiones Innovadoras.  El Profesional de la Informaci&oacute;n, 17 (1). 
 
D&iacute;az-P&eacute;rez, M., Giradles Reyes, R. and Armas Pe&ntilde;as, D. (2008).Principales resultados de innovaci&oacute;n 
tecnol&oacute;gica de Cuba en Estados Unidos: una visi&oacute;n desde las patentes. Ciencias de la Informaci&oacute;n, 39 (2). 
 
D&iacute;az-P&eacute;rez M, Gir&aacute;ldez Reyes, R., Armas Pe&ntilde;as, D. and Govea Gonz&aacute;lez, M.R. (2009).An&aacute;lisis 
patentom&eacute;trico de la informaci&oacute;n desde la perspectiva de g&eacute;nero. ACIMED, 20(2). 
 
D&iacute;az-P&eacute;rez, M., Rivero, S. and Moya-Aneg&oacute;n, F. (2010).Producci&oacute;n tecnol&oacute;gica latinoamericana con 
mayor visibilidad internacional: 1996-2007. Un estudio de caso: Brasil. Revista Espa&ntilde;ola de 
Documentaci&oacute;n Cient&iacute;fica, 33 (1), 34-62. 
 
diBiaggio, L. and Nesta, L. (2005). Statistics, Knowledge Specialization and the Organization of 
Competencies  Industrielle. 
</p>
<p>Fall, C.J., et. al. (2003).Automated categorization in the international patent classification. ACM SIGIR 
Forum, 37(1), 10 25. 
 
Gir&aacute;ldez, R., D&iacute;az-P&eacute;rez, M.and Armas, D. (2008).PROInTec: un software para el tratamiento inteligente 
de datos sobre patentes. ACIMED, 17 (5). 
 
Gonz&aacute;lez-Albo-Manglano, B. and Zulueta-Garc&iacute;a, M.A. (2007).Patentes dom&eacute;sticas de universidades 
espa&ntilde;olas: an&aacute;lisis bibliom&eacute;trico. Revista espa&ntilde;ola de documentaci&oacute;n cient&iacute;fica, 30 (1), 61-90. 
 
Gupta, V. K., and Pangannaya, N. B. (2000).Carbonnanotubes: Bibliometricanalysis of patents. 
WorldPatentInformation, 22, 185 189. 
 
Guerrero-Bote, V., Zapico-Alonso, F. Espinosa-Calvo, M.E., G&oacute;mez Crisostomo, R. and Moya-Aneg&oacute;n, 
F. (2006). Binary  improvement to the  algorithm. InformationProcessing and 
Management, 42, 1484 1490. 
 
Guzm&aacute;n, M.V., Carrillo, H. and Jim&eacute;nez, J.L. (2010).Bioinformetric Studies on TB Vaccines Research. 
The art science of Tuberculosis vaccine development. pp 425-441. Penerbit Universiti Sains Malaysia. 
 
Grupp, H., Schmoch, U. and Kuntze, U. (1991). Patents as potential indicators of the utility of EC 
research programmes. Scientometrics,21(3), 417-445. 
 
Haupt, R., Kloyer, M., and Lange, M. (2007). Patent indicators for the technology life cycle development. 
Research Policy, 36, 387 398. 
 
Hesseling, A.C. et. al. (2007).The risk of disseminated bacilli Calmette-Guerin (BCG) disease in HIV-
infected children. Vaccine, 25(1), 14 18. 
 
Horwitz, M.A., et.al.(2005). Enhancing the protective efficacy of Mycobacterium bovis BCG vaccination 
against tuberculosis by boosting with the Mycobacterium tuberculosismajor secretory protein . Infect 
Immun,73(8), 4676 83. 
 
Horwitz, M.A.,et. al. (1995). Protective immunity against tuberculosis induced by vaccination with major 
extracellular proteins of Mycobacterium tuberculosis. ProcNatlAcad.Sci U S A, 92(5), 1530 4. </p>
<p/>
</div>
<div class="page">
<p/>
<p> 
Horwitz, M.A., Harth, G., Dillon, B.J. and Maslesa-Galic, S. (2000). Recombinant bacillus calmette-
guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein 
induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly 
susceptible animal model.  ProcNatlAcadSci USA, 97, 13853 8. 
 
Huang, Z., Chen, H, Yan, L. andRoco, M.C. (2005). Longitudinal nanotechnology development (1991
2002): National Science Foundation funding and its impact on patents. Journal of Nanoparticle Research, 
7, 343 376. 
 
Hullmann, A. (2007). Measuring and assessing the development of nanotechnology. Scientometrics, 
70,739 758. 
 
Hullmann, A. and Meyer, M. (2003). Publications and patents in nanotechnology an overview of 
previous studies and the state of the art. Scientometrics, 58 (3), 507 527.  
 
Jaffe A.B. and Trajtenberg, M. (2002).Patents, Citations &amp; Innovations: A Window on the Knowledge 
Economy. MIT Press. 
</p>
<p>Jaques, M.(2001).Patent Citation Analysis. Scientometrics, 51(1), 185-201. 
 
Kaufmann, S.H., Hussey, G. and Lambert, P.H. (2010). New vaccines for tuberculosis.Lancet.375 (9731), 
2110 9. 
 
Kaufmann, S.H.(2010).Future vaccination strategies against tuberculosis: thinking outside the box. Immu
nity, 33(4), 567 77.  
 
Kaufmann, S.H.(2011).Fact and fiction in tuberculosis vaccine research: 10 years later. Lancet Infect. Dis.
,11(8), 633 40.  
 
Kaufmann, S.H. (2002). Protection against tuberculosis: cytokines, T cells, and macrophages.  
Ann Rheum Dis 61(2), 54 58.  
 
Kaufmann, S.H. and McMichael, A.J. (2005). Annulling a dangerous liaison: Vaccination  
strategies against AIDS and tuberculosis. Nature Medicine, 11, 33-44. 
 
Kuusi, O. and  Meyer, M. (2007). Anticipating technological breakthroughs: Using bibliographic 
coupling to explore the nanotubes paradigm. Scientometrics, 70, 759 777. 
 
Klitkou, A. and Gulbrandsen, M. (2010).The relationship between academic patenting 
publishing in Norway. Scientometrics, 82,93 108. 
 
Leydesdorff, L. (1987). Various methods for the Mapping of Science. Scientometrics 11, 291-320. 
</p>
<p>Leydesdorff, L. (2004). The university industry knowledge relationship: Analyzing patents and the 
science base of technologies. Journal of the American Society for Information Science &amp; Technology, 55 
(11), 991 1001. 
 
Leydesdorff, L. (2008a). The delineation of nanoscience and nanotechnology in terms of journals and 
patents: A most recent update. Scientometrics, 76 (1), 159 167. 
 
Leydesdorff, L. (2008b). Patent Classifications as Indicators of Intellectual Organization. Journal of the 
American Society for Information Science and Technology, 59(10), 1582 1597.  
 
Leydesdorff, L. and Heimeriks, G. (2001). The self organization of the European Information Society: the 
</p>
<p>Journal of the American Society for information Science and Technology 52, 
(14),1262-1274. 
 
Li, X., Chen, H., Huang, Z. andRoco, M.C. (2007). Patent citation network in nanotechnology (1976
2004). J Nanopart Res, 9 (3), 337 352. </p>
<p/>
</div>
<div class="page">
<p/>
<p> 
Li Z., Howard A., Kelley C., Delogu G., Collins F., and Morris S. (1999). Immunogenicity of DNA 
vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect 
Immun, 67, 4780 6. 
 
Lozes E., Huygen K., Content J., Denis O., Montgomery D.L., Yawman A.M. ,et. al.. (1997). 
Immunogenicity and efficacy of a Tuberculosis DNA vaccine encoding the components of the secreted 
antigen 85 complex. Vaccine, 15, 830 3. 
 
Martin, C., Bigi, F. and Gicquel, B. (2007). Chapter 10: New Vaccines against Tuberculosis. 
Tuberculosis. From basic science to patient care 2007, pp341-360. 
 
Meyer, M. (2000). Patent citations in a novel field of technology What can they tell about interactions 
between emerging communities of science and technology? Scientometrics, 48, 151 178. 
 
Meyer, M. (2001). Patent citation analysis in a novel field of technology: An exploration of nano-science 
and nano-technology. Scientometrics, 51, 163 183. 
 
Meyer, M. (2006). Are patenting scientists the better scholars? An exploratory comparison of inventor  
authors with their non-inventing  peers in nano-science and  technology.Research Policy, 35, 1646 1662. 
 
</p>
<p>Meyer, M., and Persson, O. (1998). Nanotechnology-interdisciplinarity, patterns of collaboration and 
differences in application. Scientometrics, 42, 195 205. 
 
Michel, J. and Bernd, B. (2001). Patent citation analysis a closer look at the basic input data from patent 
search reports. Scientometrics, 51(1),185-201. 
 
Mohd-Nor, N., Acosta, A. and Sarmiento, M.E. (2010). The art science of Tuberculosis vaccine 
development. pp 634.Penerbit Universiti Sains Malaysia. 
 
Mori, T. (2000).Recent Trends in Tuberculosis, Japan. Emerging Infectious Diseases Journal. 6(6), 566-
568. 
 
Moya-Aneg&oacute;n, F., Vargas-Quesada, B., Herrero-Solana, V., Chinchilla-Rodr&iacute;guez, Z., Corera-&Aacute; lvarez, 
E. and Mun&oacute;z-Fern&aacute;ndez, F. J. (2004). A new technique for building map
based on the cocitation of classes and categories. Scientometrics, 61(1), 129 145. 
 
Moya- Aneg&oacute;n,F.Chinchilla,Z.Corera, E. and D&iacute;az-P&eacute;rez, M. (2011). Estudio de la producci&oacute;ncient&iacute;fica y 
tecnol&oacute;gica en colaboraci&oacute;n Universidad-Empresa en Iberoam&eacute;rica. REDEMPRENDIA 
 
Narin, F. (1994).Patent bibliometrics.Scientometrics, 30, 147 155. 
 
Narin, F. (1995).Patents as indicators for the evaluation of industrial research output. Scientometrics, 
34(3), 489-496. 
 
Narin, F., and Olivastro, D. (1988). Technology indicators based on patents and patent citations. In A. F. 
J. Van Raan (Ed.), Handbook of quantitative studies of science and technology. North Holland: Elsevier 
Publishers. 
 
Pao-Long, C., Chao-Chan, W. and Hoang-Jyh, L. (2010).Using patent analyses to monitor the 
technological trends in an emerging field of technology: a case of carbon nanotube field emission display.  
Scientometrics, 82,5 19. 
 
Pavitt, K. (1985). Patent statistics as indicators of innovative activities: possibilities and problems. 
Scientometrics, 7 (1-2), 77-99. 
 
Pavitt, K. (1988).Uses and abuses of patent statistics. En Van Raan, A.F.J. (ed.), Handbook of 
Quantitative Studies of Science and Technology. Elsevier Science Publishers B.V. North Holland. 
 </p>
<p/>
</div>
<div class="page">
<p/>
<p>Pei-Chun, L., Hsin-Ning, S. and Feng-Shang, W. (2010). Quantitative mapping of patented technology  
The case of electrical conducting polymer nanocomposite. Technological Forecasting &amp; Social Change, 
77, 466 478. 
 
Perianes-Rodr&iacute;guez, A., Olmeda-G&oacute;mez, C. and Moya-Aneg&oacute;n, F. (2010). Detecting, identifying and 
visualizing research groups in co-authorship networks. Scientometrics, 82,307 319. 
 
Porter, A. L. and Cunningham, S. W. (2004) TechMining: Exploiting New Technologies for Competitive 
Advantage. John Wiley&amp;Sons. 
</p>
<p>Sheu, M. et. al, 2006). Mapping nanotechnology patents: The EPO approach. World Patent Information, 
28, 204 211. 
 
Skeiky, Y.A. andSadoff,C. (2006). Advances in tuberculosis vaccine strategies. Nat Rev Microbiol, 4(6), 
469 76. 
 
Skeiky, Y.A.,et.al.(2004a).Differential immune responses and protective efficacy induced by components 
of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immun
ol, 172(12),7618 28.  
 
Skeiky, Y.A.,et. al. (2004b). Differential immune responses and protective efficacy induced by 
components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant 
protein. J Immunol, 172, 7618 28. 
 
Skeiky, Y.A. and Sadoff, J.C. (2006). Advances in tuberculosis vaccine strategies. Nat Rev Microbiol, 
4,469-476. 
 
Skeiky, Y.A.et.al.. (2009).Nonclinical efficacy and safety of HyVac4:IC31 vaccine administered in 
a BCG prime boost regimen. Vaccine, 28(4), 1084 93.  
 
Schmookler, J. (1996). Invention and economic growth. Boston: Harvard University Press. 
 
Spinak, E. (1998). Indicadores cienciom&eacute;tricos. Ci&ecirc;ncia da informa&ccedil;&atilde;o,27 (2), 141-148. 
 
Tijssen, R. J. W. (1992). Cartography of science: Scientometric mapping with multidimensional scaling 
methods. DSWO Press  (Leiden). 
</p>
<p>Trilateral Co-operation, (2005) Trilateral Statistical Report 2004. Edition Munich, Germany. 
 
Van-Looy, B.; Callaert, J.; Debackere, K. (2006). Publication and patent behaviour of academic 
researchers: conflicting, reinforcing or merely co-existing? Research Policy, 35, 596-608. 
 
Van Raan, A. F. J. and Peters, H. P. F. (1989). -  
structures. Scientometrics, 15, 607 620. 
 
Van Raan, A. F. J. and Tijssen, R. J. W. (1993). The neural net of neural network research: An exercise in 
bibliometric mapping. Scientometrics, 26, 169 192. 
 
Van Zeebroeck, et.al. (2006).Issues in measuring the degree of technological specialization with patent 
data. Scientometrics, 66 (3), 481 492. 
 
Vargas-Quesada, B., and Moya-Aneg&oacute;n, F. (2007).Visualizing the structure of science. Berlin: Springer. 
 
Verspagen, B. (2007). Mapping technological trajectories as patent citation networks: A study on the 
historyof fuel cell research. Advances in Complex Systems, 10, 93 115. 
 
Yoon, B., and Park, Y. (2004). A text-mining-based patent network: Analytical tool for high-technology 
trend. Journal of high technology management research, 15, 37 50. </p>
<p/>
</div>
<div class="page">
<p/>
<p>Case Study of the Technical Status of a Technological Domain 
 
</p>
<p>Highlights 
</p>
<p>- There is evidence that from the apparition of TB also in rich countries, more funding becameavailable, 
leading to important discoveries which have given a push to patents grants. 
</p>
<p>- The productivity peaks in TB Vaccines patents correspond to the main milestones in this field,e.g. in 1991 
New use of BCGfor recombinant vaccines  (Albert Einstein College) and "Humoral and cell-
</p>
<p>mediated immune responses to olive recombinant BCG-HIV vaccine" (Withehead); in 1998 with the 
discovery of the mycobacteria-Tuberculosis genome; and in 2001 with "Reverse vaccinology, a genome-
based approach to vaccine develoment" (Rappouli), etc. 
</p>
<p>- The geographic projection of these research projects have as its centre and largest coveragethe US, France 
and UK. It is shown that the technological productivity in terms of patents by country does not correspond 
with the countries with the highest mortality and spread of TB. Indeed, there are only 21 countries in the 
USPTO with holderships on alternative or improved vaccines still under design, despite the high risk 
humanity is suffering from TB. 
</p>
<p>- Another contribution by the research is to identify Denmark, Belgium, Germany, Canada,Korea and 
Switzerland as countries where currently new patentable vaccines are being developed, which can climb up 
to higher position in the field if they maintain their level of innovation activity in the next years. 
</p>
<p>- Amongst the most productive researchers working on prophylactic alternatives we noteAntonio Campos-
Neto, YasirSkeiky, Peter Andersen, Laura Mar&iacute;aGennaro, Jerald C. Sadoff, Davin C. Dillon, Lucas De Wit, 
etc. They come mostly from US, France, Belgium, Denmark, Germany and Canada, which corresponds 
relatively well with the productivity by country. 
</p>
<p>- The study allowed to ascertain in addition that the most important inventors are working on asustained effort 
along with an adequate patenting policy. It was shown that the inventors in this scientific discipline have an 
active scientific curriculum and that there is a close link in between basic sciences and technological 
innovation in the field of TB Vaccines. 
</p>
<p>- The most important holders of registered inventions on TB Vaccines are the Institut Pasteurof Francia and 
the Corixa Corporation of the US. Also listed with the most productive holders are : The Regents of the 
University of California (US), Statens Serum Institut (Denmark), Cornell Research Foundation Inc. (US), 
N.V. InnogeneticsS.A. (Belgium), Albert Einstein College of Medicine of Yeshiva University (US), Aeras 
Global TB Vaccine Foundation (US), The Board of Trustees of the Leland Stanford Junior University (US) 
and the University of Medicine and Dentistry of New Jersey (US). 
</p>
<p>- The strongest co-operation links exist within US patent holders, and the strongest researchlinks exist with 
research centers and academics. 
</p>
<p>- The TB Vaccines patents relate to 4 thematic areas. This shows that such researchnecessitates a wide 
scientific and technological base in order to develop patents; the raise of the Physics sector brings the most 
significant new impulse in the emerging TB Vaccines technology. 
</p>
<p>- The patents of the Corixa Corporation are the most cited ones, followed by the patents of theStatens Serum 
Institut of Denmark, the inventions of The Regents of the University of California, and the discoveries of the 
Albert Einstein College of Medicine of Yeshiva University. 
</p>
<p> </p>
<p/>
</div>
<div class="page">
<p/>
<p>Copyright Transfer Statement 
Publisher: Akad&eacute;miai Kiad&oacute; Zrt., Budapest, Hungary
</p>
<p>The signed Copyright Transfer Statement please return to: 
http://www.editorialmanager.com/scim/ 
</p>
<p>Author
Name: &hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;...
Address: &hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;... 
E-mail address: &hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;... 
</p>
<p>Article information
Title:&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip; 
Journal title: Scientometrics
Co-authors: &hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;.. 
</p>
<p>I. Transfer of copyright 
By execution of the present Statement Author transfers copyright and assigns exclusively to Publisher all rights, title and interest that Author may 
have (for the extent transferable) in and to the Article and any revisions or versions thereof, including but not limited to the sole right to print, publish 
and sell the Article worldwide in all languages and media. Transfer of the above rights is referred to as those of the final and published version of the 
Article but does not restrict Author to self-archive the preprint version of his/her paper (see Section III).  
</p>
<p>II. Rights and obligations of Publisher 
The Publisher&rsquo;s rights to the Article shall especially include, but shall not be limited to: 
</p>
<p> ability to publish an electronic version of the Article via the website of the publisher Akademiai Kiado, www.akademiai.com (in Hungary), as
well as the co-publisher&rsquo;s website, www.SpringerLink.com (outside of Hungary) or any other electronic format or means of electronic 
distribution provided by or through Akademiai Kiado or Springer from time to time, selling the Article world-wide (through subscriptions, 
Pay-per-View, single archive sale, etc.) 
</p>
<p> transforming to and selling the Article through any electronic format 
 publishing the Article in the printed Journals as listed on the official Website of Publisher
 transferring the copyright and the right of use of the Article onto any third party 
 translating the Article 
 taking measures on behalf of the Author against infringement, inappropriate use of the Article, libel or plagiarism. 
</p>
<p>Publisher agrees to send the text of the Article to the e-mail address of Author indicated in the present Statement for preview before the first 
publishing either in paper and/or electronic format (Proof). Author shall return the corrected text of the Article within  2  days to the Publisher. Author 
shall, however, not make any change to the content of the Article during the First Proof preview.  
</p>
<p>III. Rights and obligations of Author 
The Author declares and warrants that he/she is the exclusive author of the Article &ndash; or has the right to represent all co-authors of the Article (see 
Section IV) &ndash; and has not granted any exclusive or non-exclusive right to the Article to any third party prior to the execution of the present Statement 
and has the right therefore to enter into the present Statement and entitle the Publisher the use of the Article subject to the present Statement.  By 
executing the present Statement Author confirms that the Article is free of plagiarism, and that Author has exercised reasonable care to ensure that it 
is accurate and, to the best of Author&rsquo;s knowledge, does not contain anything which is libelous, or obscene, or infringes on anyone&rsquo;s copyright, right of 
privacy, or other rights. The Author expressively acknowledges and accepts that he/she shall be entitled to no royalty (or any other fee) related to any 
use of the Article subject to the present Statement. The Author further accepts that he/she will not be entitled to dispose  of the copyright of the final, 
published version of the Article or make use of this version of the Article in any manner after the execution of the present Statement. The Author is 
entitled, however, to self-archive the preprint version of his/her manuscript. The preprint version is the Author&rsquo;s manuscript or the galley proof or the 
Author&rsquo;s manuscript along with the corrections made in the course of the peer review process. The Author&rsquo;s right to self-archive is irrespective of the 
format of the preprint (.doc, .tex., .pdf) version and self-archiving includes the free circulation of this file via e-mail or publication of this preprint on the 
Author&rsquo;s webpage or on the Author&rsquo;s institutional repository with open or restricted access. When self-archiving a paper the Author should clearly 
declare that the archived file is not the final published version of the paper, he/she should quote the correct citation and enclose a link to the 
published paper (http://dx.doi.org/[DOI of the Article without brackets]).  
</p>
<p>IV. Use of third party content as part of the Article 
When not indicating any co-authors in the present Statement Author confirms that he/she is the exclusive author of the Article. When indicating co-
authors in the present Statement Author declares and warrants that all co-authors have been listed and Author has the exclusive and unlimited right 
to represent all the co-authors of the Article and to enter into the present Statement on their behalf and as a consequence all declarations made by 
Author in the present Statement are made in the name of the co-authors as well. Author also confirms that he/she shall hold Publisher harmless of all 
third-party claims in connection to non-authorized use of the Article by Publisher. Should Author wish to reuse material sourced from third parties 
such as other copyright holders, publishers, authors, etc. as part of the Article, Author bears responsibility for acquiring and clearing of the third party 
permissions for such use before submitting the Article to the Publisher for acceptance. Author shall hold Publisher harmless from all third party claims 
in connection to the unauthorized use of any material under legal protection forming a part of the Article.  
</p>
<p>V. Other provisions 
Subject to the present Statement the Article shall be deemed as first published within the Area of the Hungarian Republic. Therefore the provisions of 
the Hungarian law, especially the provisions of Act LXXVI of 1999 on Copy Rights shall apply to the rights of the Parties with respect to the Article. 
For any disputes arising from or in connection with the present Statement Parties agree in the exclusive competence of the Central District Court of 
Pest or the Capital Court of Budapest respectively.  
</p>
<p>&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;&hellip;..
Date and place of signature  
</p>
<p>   
</p>
<p>  
    
</p>
<p>
</p>
<p>       
</p>
<p>          </p>
<p/>
</div>
<div class="page">
<p/>
<p>http://www.springer.com/journal/11192</p>
<p/>
</div>
</body>
</html>
